Clare Mills
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Clare Mills has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
- Thomas Waterfield
Wellcome Wolfson Institute of Experimental Medicine, Queen’s University Belfast, Belfast, UK
10 shared publications Holly Drummond
Wellcome Wolfson Institute of Experimental Medicine, Queen’s University Belfast, Belfast, UK
6 shared publications- Etimbuk Umana
School of Medicine, University College Dublin
5 shared publications - Helen Elizabeth Groves
Wellcome-Wolfson Institute For Experimental Medicine, Queen’s University Belfast, BT9 7BL Belfast, United Kingdom
5 shared publications Thomas Waterfield
Wellcome Wolfson Institute of Experimental Medicine, Queen's University Belfast, 97 Lisburn Road, BT9 7BL Belfast, UK
5 shared publicationsEtimbuk Umana
Wellcome Wolfson Institute of Experimental Medicine, Queen's University Belfast, 97 Lisburn Road, BT9 7BL Belfast, UK
4 shared publications
Latest Publications
- Open Access
- 23 October 2026
- Published by Elsevier in The Lancet Microbe
- p. 101538
Biomarker tests for invasive Candida infection in critically ill patients in the UK (A-Stop): a multicentre diagnostic test accuracy study
- 23 October 2026
- Published by Elsevier in The Lancet Microbe
- p. 101538
Open AccessBiomarker tests for invasive Candida infection in critically ill patients in the UK (A-Stop): a multicentre diagnostic test accuracy study
- Open Access
- 23 July 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 6817
Absent pleocytosis in infant viral central nervous system infections reflects lymphocyte depletion and cytokine activation
- 23 July 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 6817
Open AccessAbsent pleocytosis in infant viral central nervous system infections reflects lymphocyte depletion and cytokine activation
- Open Access
- 16 June 2026
- Published by National Institute for Health and Care Research in NIHR Open Research
- Vol. 6, 67
Age-specific Reference Intervals for Serum GFAP and UCH-L1 in Children and Adolescents
Background Glial fibrillary acidic protein (GFAP) and ubiquitin C-terminal hydrolase L1 (UCH-L1) are promising blood biomarkers for reducing unnecessary CT imaging in children with mild traumatic brain injury (mTBI). However, paediatric reference intervals (RIs) and age-related variation in biomarker concentrations remains poorly defined. This study aimed to establish paediatric RIs for GFAP and UCH-L1 and to determine the need for age-or sex-specific interpretation. Methods Serum samples were obtained from a cohort of healthy children aged 2–16 years enrolled in the Rapid Diagnostics Antibody Testing and Host Response in Children with COVID-19 (RAPID-19) study (ClinicalTrials.gov NCT04347408). Samples were collected at five UK sites between April–July 2020. Biomarkers were measured using the VIDAS® TBI (GFAP, UCH-L1) assay. Reference intervals were generated according to CLSI EP28-A3c guidelines. Upper reference intervals (97.5th) were determined, and biomarker levels were examined for sex and age associations. Results The study included 370 children. GFAP showed a continuous age-related decline, necessitating three age partitions (2- < 5, 5- < 10, 10- < 16 years), whereas UCH-L1 exhibited no meaningful age or sex effect. Adult VIDAS® cut-offs produced high false-positive rates for GFAP in younger children (2- < 5 years: 72.3%; 5- < 10 years: 28.4%), but minimal impact in adolescents and for UCH-L1 (4.8%). Continuous reference intervals demonstrated wide confidence limits in early childhood, narrowing with age. Conclusions We report the first paediatric RIs for GFAP and UCH-L1 using the VIDAS® TBI assay. GFAP displays marked age dependence, while UCH-L1 remains stable across childhood. These findings provide a necessary foundation for biomarker-guided assessment of mTBI in children.
- 16 June 2026
- Published by National Institute for Health and Care Research in NIHR Open Research
- Vol. 6, 67
Open AccessAge-specific Reference Intervals for Serum GFAP and UCH-L1 in Children and Adolescents
Background Glial fibrillary acidic protein (GFAP) and ubiquitin C-terminal hydrolase L1 (UCH-L1) are promising blood biomarkers for reducing unnecessary CT imaging in children with mild traumatic brain injury (mTBI). However, paediatric reference intervals (RIs) and age-related variation in biomarker concentrations remains poorly defined. This study aimed to establish paediatric RIs for GFAP and UCH-L1 and to determine the need for age-or sex-specific interpretation. Methods Serum samples were obtained from a cohort of healthy children aged 2–16 years enrolled in the Rapid Diagnostics Antibody Testing and Host Response in Children with COVID-19 (RAPID-19) study (ClinicalTrials.gov NCT04347408). Samples were collected at five UK sites between April–July 2020. Biomarkers were measured using the VIDAS® TBI (GFAP, UCH-L1) assay. Reference intervals were generated according to CLSI EP28-A3c guidelines. Upper reference intervals (97.5th) were determined, and biomarker levels were examined for sex and age associations. Results The study included 370 children. GFAP showed a continuous age-related decline, necessitating three age partitions (2- < 5, 5- < 10, 10- < 16 years), whereas UCH-L1 exhibited no meaningful age or sex effect. Adult VIDAS® cut-offs produced high false-positive rates for GFAP in younger children (2- < 5 years: 72.3%; 5- < 10 years: 28.4%), but minimal impact in adolescents and for UCH-L1 (4.8%). Continuous reference intervals demonstrated wide confidence limits in early childhood, narrowing with age. Conclusions We report the first paediatric RIs for GFAP and UCH-L1 using the VIDAS® TBI assay. GFAP displays marked age dependence, while UCH-L1 remains stable across childhood. These findings provide a necessary foundation for biomarker-guided assessment of mTBI in children.
- Open Access
- 3 June 2026
- Published by Elsevier in Journal of Infection
- Vol. 93 (1) , 106782
Proteomic biomarkers differentiate bacterial infections in febrile infants: A multicentre prospective study
- 3 June 2026
- Published by Elsevier in Journal of Infection
- Vol. 93 (1) , 106782
Open AccessProteomic biomarkers differentiate bacterial infections in febrile infants: A multicentre prospective study
- Open Access
Proteomic Biomarkers Differentiate Bacterial Infections in Febrile Infants: A Multicentre Prospective Study
Objectives: To identify and validate plasma host-response protein biomarkers that improve discrimination of bacterial infection in febrile infants ≤90 days of age, and to assess whether novel biomarkers add value beyond established markers. Methods: Sub-study of the prospective multicentre Febrile Infant Diagnostic Assessment and Outcome (FIDO) cohort. Novel biomarkers were identified through plasma proteomic profiling (Olink®) and combined with biomarkers and signatures from the literature for verification using Luminex and ELISA platforms. Diagnostic performance of novel biomarkers, established markers (CRP, PCT), and multi-protein signatures was evaluated. Results: Proteomic profiling of 110 samples identified 174 proteins differentially expressed between bacterial and viral infections, revealing distinct pathogen-specific immune signatures. Verification in the full cohort (n=445) demonstrated PCT had the highest individual accuracy for invasive bacterial infection (IBI) (AUC 0.89). Combining PCT with novel biomarkers, particularly lipocalin-2 (LCN2), improved discrimination (AUC 0.96). Diagnostic performance for the combined IBI/urinary tract infection (UTI) outcome was consistently lower (AUC <0.8). Conclusions: Febrile infants demonstrate biologically coherent host-response signatures that can be leveraged diagnostically. A PCT–LCN2 combination showed excellent accuracy for identifying IBI and may support future biomarker-guided diagnostic strategies, while reliable discrimination of UTI remains challenging.
Open AccessProteomic Biomarkers Differentiate Bacterial Infections in Febrile Infants: A Multicentre Prospective Study
Objectives: To identify and validate plasma host-response protein biomarkers that improve discrimination of bacterial infection in febrile infants ≤90 days of age, and to assess whether novel biomarkers add value beyond established markers. Methods: Sub-study of the prospective multicentre Febrile Infant Diagnostic Assessment and Outcome (FIDO) cohort. Novel biomarkers were identified through plasma proteomic profiling (Olink®) and combined with biomarkers and signatures from the literature for verification using Luminex and ELISA platforms. Diagnostic performance of novel biomarkers, established markers (CRP, PCT), and multi-protein signatures was evaluated. Results: Proteomic profiling of 110 samples identified 174 proteins differentially expressed between bacterial and viral infections, revealing distinct pathogen-specific immune signatures. Verification in the full cohort (n=445) demonstrated PCT had the highest individual accuracy for invasive bacterial infection (IBI) (AUC 0.89). Combining PCT with novel biomarkers, particularly lipocalin-2 (LCN2), improved discrimination (AUC 0.96). Diagnostic performance for the combined IBI/urinary tract infection (UTI) outcome was consistently lower (AUC <0.8). Conclusions: Febrile infants demonstrate biologically coherent host-response signatures that can be leveraged diagnostically. A PCT–LCN2 combination showed excellent accuracy for identifying IBI and may support future biomarker-guided diagnostic strategies, while reliable discrimination of UTI remains challenging.
- Open Access
- 5 February 2026
- Published by MDPI AG in Preprints.org
Metagenomic Next-Generation Sequencing to Characterise the Respiratory Microbiome in Paediatric Patients with Cystic Fibrosis: A Scoping Review Protocol
Objective: To summarise the evidence on the use of metagenomic next-generation sequencing to characterise the respiratory microbiome in paediatric patients with cystic fibrosis (CF), with a focus on early-life microbial evolution, development of the airway resistome and the clinical utility of sequencing-based approaches in practice. Introduction: Early-life development of the respiratory microbiome plays a significant role in shaping long-term pulmonary outcomes in children with CF. Conventional culture-based diagnostics lack the sensitivity required to capture the complexity of airway microbial communities. Metagenomic sequencing enables culture-independent identification of pathogens and antimicrobial resistance genes, resulting in an expansion of literature utilising sequencing-based approaches to characterise the CF respiratory microbiome. The clinical significance of early-life microbiome variation and the translational value of these data remain poorly understood. Eligibility Criteria: Inclusion- studies that utilise metagenomic sequencing, including targeted 16S rRNA amplicon sequencing and untargeted shotgun sequencing, to characterise the bacterial respiratory microbiome of children and young people up to their 18th birthday with CF. Exclusion- animal models; in vitro, tissue-based or in silico studies; case-studies <10 participants, editorials, conference abstracts and review studies. Methods: The review will be conducted in accordance with Joanna Briggs Institute and PRISMA-Scoping Review (ScR) methodology. The databases to be searched will include Medline, and Web of Science with an additional for grey literature search via Google and Google Scholar, with no time or language restrictions. Two independent reviewers will screen by title and abstract, then by full-text review. The results of the search, study selection process and reasons for exclusion at full-text review will be reported in the PRISMA-ScR flow diagram. Data will be extracted into a chart. Key study characteristics and findings will be presented and discussed descriptively, supported by tabular summaries; highlighting how the available evidence relates to the review question.
- 5 February 2026
- Published by MDPI AG in Preprints.org
Open AccessMetagenomic Next-Generation Sequencing to Characterise the Respiratory Microbiome in Paediatric Patients with Cystic Fibrosis: A Scoping Review Protocol
Objective: To summarise the evidence on the use of metagenomic next-generation sequencing to characterise the respiratory microbiome in paediatric patients with cystic fibrosis (CF), with a focus on early-life microbial evolution, development of the airway resistome and the clinical utility of sequencing-based approaches in practice. Introduction: Early-life development of the respiratory microbiome plays a significant role in shaping long-term pulmonary outcomes in children with CF. Conventional culture-based diagnostics lack the sensitivity required to capture the complexity of airway microbial communities. Metagenomic sequencing enables culture-independent identification of pathogens and antimicrobial resistance genes, resulting in an expansion of literature utilising sequencing-based approaches to characterise the CF respiratory microbiome. The clinical significance of early-life microbiome variation and the translational value of these data remain poorly understood. Eligibility Criteria: Inclusion- studies that utilise metagenomic sequencing, including targeted 16S rRNA amplicon sequencing and untargeted shotgun sequencing, to characterise the bacterial respiratory microbiome of children and young people up to their 18th birthday with CF. Exclusion- animal models; in vitro, tissue-based or in silico studies; case-studies <10 participants, editorials, conference abstracts and review studies. Methods: The review will be conducted in accordance with Joanna Briggs Institute and PRISMA-Scoping Review (ScR) methodology. The databases to be searched will include Medline, and Web of Science with an additional for grey literature search via Google and Google Scholar, with no time or language restrictions. Two independent reviewers will screen by title and abstract, then by full-text review. The results of the search, study selection process and reasons for exclusion at full-text review will be reported in the PRISMA-ScR flow diagram. Data will be extracted into a chart. Key study characteristics and findings will be presented and discussed descriptively, supported by tabular summaries; highlighting how the available evidence relates to the review question.
- Open Access
- 21 November 2025
- Published by Elsevier in eClinicalMedicine
- Vol. 90
Diagnostic test accuracy of dipstick urinalysis in clean catch urine for urinary tract infection in febrile infants presenting to emergency departments: a post-hoc analysis of the FIDO study
- 21 November 2025
- Published by Elsevier in eClinicalMedicine
- Vol. 90
Open AccessDiagnostic test accuracy of dipstick urinalysis in clean catch urine for urinary tract infection in febrile infants presenting to emergency departments: a post-hoc analysis of the FIDO study
- Open Access
Neuroinflammatory and immune responses in infants with enterovirus and parechovirus meningitis, and their association with CSF pleocytosis
Objectives: Enterovirus (EV) and parechovirus (PeV) meningitis are significant causes of illness in febrile infants. The clinical significance of detecting EV/PeV in the CSF, particularly in the absence of pleocytosis and neurological symptoms, remains uncertain in this age group. We aimed to characterise the relationship between clinical features, systemic neuroinflammatory and immune responses, and CSF pleocytosis in infants with EV/PeV meningitis. Methods: Prospective multicentre observational cohort study of febrile infants <90 days old undergoing CSF testing for infection. Infants were recruited as part of the Febrile Infant Diagnostic Assessment and Outcome (FIDO) Study from 35 Paediatric Emergency Research in the UK and Ireland (PERUKI) sites from 6th July 2022 to 31st August 2023 ( NCT05259683 ). Plasma proteomic profiling of 724 inflammation and neurology-related proteins was performed using Olink technology and compared with clinical and laboratory data. Results: 603 febrile infants were included, with 21/603 (3·5%) PeV, and 173/197 (28.7%) EV meningitis cases. Lymphopenia was significantly more common in infants without pleocytosis, 62/101 (63.9%), than those with pleocytosis 7/54 (16.7%). No significant differences in clinical symptoms or timing of presentation were observed with differing CSF WBC counts. Proteomic analysis (n=131) revealed that infants without pleocytosis exhibited elevated inflammatory cytokine responses and enrichment of pathways related to apoptosis and CNS involvement. In contrast, those with pleocytosis showed muted cytokine responses. Conclusions: The absence of CSF pleocytosis in EV and PeV meningitis may result from systemic lymphocyte depletion, potentially mediated by cytokine-driven apoptosis. Our findings do not support the hypothesis that the lack of pleocytosis is primarily attributable to early presentation or to incidental detection of viral RNA due to viremia in infants.
Open AccessNeuroinflammatory and immune responses in infants with enterovirus and parechovirus meningitis, and their association with CSF pleocytosis
Objectives: Enterovirus (EV) and parechovirus (PeV) meningitis are significant causes of illness in febrile infants. The clinical significance of detecting EV/PeV in the CSF, particularly in the absence of pleocytosis and neurological symptoms, remains uncertain in this age group. We aimed to characterise the relationship between clinical features, systemic neuroinflammatory and immune responses, and CSF pleocytosis in infants with EV/PeV meningitis. Methods: Prospective multicentre observational cohort study of febrile infants <90 days old undergoing CSF testing for infection. Infants were recruited as part of the Febrile Infant Diagnostic Assessment and Outcome (FIDO) Study from 35 Paediatric Emergency Research in the UK and Ireland (PERUKI) sites from 6th July 2022 to 31st August 2023 ( NCT05259683 ). Plasma proteomic profiling of 724 inflammation and neurology-related proteins was performed using Olink technology and compared with clinical and laboratory data. Results: 603 febrile infants were included, with 21/603 (3·5%) PeV, and 173/197 (28.7%) EV meningitis cases. Lymphopenia was significantly more common in infants without pleocytosis, 62/101 (63.9%), than those with pleocytosis 7/54 (16.7%). No significant differences in clinical symptoms or timing of presentation were observed with differing CSF WBC counts. Proteomic analysis (n=131) revealed that infants without pleocytosis exhibited elevated inflammatory cytokine responses and enrichment of pathways related to apoptosis and CNS involvement. In contrast, those with pleocytosis showed muted cytokine responses. Conclusions: The absence of CSF pleocytosis in EV and PeV meningitis may result from systemic lymphocyte depletion, potentially mediated by cytokine-driven apoptosis. Our findings do not support the hypothesis that the lack of pleocytosis is primarily attributable to early presentation or to incidental detection of viral RNA due to viremia in infants.
- Open Access
Novel blood protein biomarkers for distinguishing bacterial from non-bacterial infection in children: a case–control study
Background: Distinguishing bacterial from viral or inflammatory conditions in hospitalised children is clinically challenging due to overlapping clinical features and limitations of existing diagnostics. Culture-based tests are slow, and commonly used biomarkers such as C-reactive protein (CRP) lack sufficient accuracy, contributing to empirical antibiotic use and antimicrobial resistance. We aimed to evaluate the diagnostic performance of novel blood protein biomarkers for bacterial infection in children admitted with infection or inflammatory illness. Methods: We performed a prospective case–control study of children ≤16 years admitted to the Royal Belfast Hospital for Sick Children (2020–2023) with bacterial infection, viral infection or inflammatory illness. Plasma samples were analysed for previously reported novel biomarkers and signatures (LCN2; TRAIL+IP-10+CRP; E-selectin+IL18+ NCAM1+LCN2+IFN-γ+LG3BP and E-selectin+IL18+ NCAM1+LCN2+IFN-γ). The diagnostic accuracy of individual biomarkers and biomarker signatures was assessed using ROC curves. Results: Fifty-two children were included (13 bacterial, 20 viral, 19 inflammatory). All evaluated biomarker signatures and LCN2 distinguished bacterial from viral infection (AUC 0.819– 0.935), with the TRAIL+IP-10+CRP signature achieving the highest accuracy (AUC 0.935). In bacterial–inflammatory comparisons, performance was lower (AUCs 0.607–0.745); the E-selectin+IL-18+NCAM1+LCN2+IFN-γ signature performed best (AUC 0.745) and outperformed CRP (AUC 0.595). A novel three-protein signature (E-selectin+LCN2+IFN-γ) had a significantly higher AUC than CRP for distinguishing bacterial infections from non-bacterial (viral and inflammatory combined). Conclusions: Several novel host protein biomarkers and signatures had a higher diagnostic accuracy than CRP for differentiating bacterial from non-bacterial illness (viral and inflammatory) in hospitalised children. These findings support the potential of biomarker-guided diagnostics to improve accuracy and facilitate earlier antibiotic de-escalation.
Open AccessNovel blood protein biomarkers for distinguishing bacterial from non-bacterial infection in children: a case–control study
Background: Distinguishing bacterial from viral or inflammatory conditions in hospitalised children is clinically challenging due to overlapping clinical features and limitations of existing diagnostics. Culture-based tests are slow, and commonly used biomarkers such as C-reactive protein (CRP) lack sufficient accuracy, contributing to empirical antibiotic use and antimicrobial resistance. We aimed to evaluate the diagnostic performance of novel blood protein biomarkers for bacterial infection in children admitted with infection or inflammatory illness. Methods: We performed a prospective case–control study of children ≤16 years admitted to the Royal Belfast Hospital for Sick Children (2020–2023) with bacterial infection, viral infection or inflammatory illness. Plasma samples were analysed for previously reported novel biomarkers and signatures (LCN2; TRAIL+IP-10+CRP; E-selectin+IL18+ NCAM1+LCN2+IFN-γ+LG3BP and E-selectin+IL18+ NCAM1+LCN2+IFN-γ). The diagnostic accuracy of individual biomarkers and biomarker signatures was assessed using ROC curves. Results: Fifty-two children were included (13 bacterial, 20 viral, 19 inflammatory). All evaluated biomarker signatures and LCN2 distinguished bacterial from viral infection (AUC 0.819– 0.935), with the TRAIL+IP-10+CRP signature achieving the highest accuracy (AUC 0.935). In bacterial–inflammatory comparisons, performance was lower (AUCs 0.607–0.745); the E-selectin+IL-18+NCAM1+LCN2+IFN-γ signature performed best (AUC 0.745) and outperformed CRP (AUC 0.595). A novel three-protein signature (E-selectin+LCN2+IFN-γ) had a significantly higher AUC than CRP for distinguishing bacterial infections from non-bacterial (viral and inflammatory combined). Conclusions: Several novel host protein biomarkers and signatures had a higher diagnostic accuracy than CRP for differentiating bacterial from non-bacterial illness (viral and inflammatory) in hospitalised children. These findings support the potential of biomarker-guided diagnostics to improve accuracy and facilitate earlier antibiotic de-escalation.
- Open Access
A single centre randomised, feasibility study using point-of-care (POC) testing for respiratory viruses to direct oral corticosteroids use in preschool-aged children with acute wheeze. A Protocol
Background: Wheezing in the pre-school aged group (under 5 years) is a common presentation and significant healthcare burden. It is a heterogenous presentation representing a spectrum of phenotypes and although the causes may be multifactorial, viral infection is the most common trigger, with rhinovirus and Respiratory Syncytial Virus (RSV) being the most commonly detected. Rigorous evidence-based guidance for the acute management of preschool wheeze (PW) with respect to which children likely to benefit from oral corticosteroid therapy (OCS), is lacking. RCTs of OCS use in PW have not adequately assessed the impact of respiratory virus testing in the management of PW. To address the hypothesis that OCS response may be determined by the specific virus, the feasibility of performing POC respiratory virus tests prior to randomisation in an acute paediatric ED setting needs to be ascertained. Methods: The PRECISE Study will be a single centre, randomised, open-label, feasibility trial. Children aged 24-59 months with acute wheeze will be eligible if the clinician is uncertain if there is a role for oral corticosteroid therapy or not. At enrolment, participants will undergo a nasal swab for rapid respiratory virus testing. Children will be randomised in a 1:1 ratio to receive oral dexamethasone or not, based on their RSV result. Participants will continue to be managed by the clinician according to local guidance. They will be invited for clinical review at 72 hours where a repeat nasal swab may be performed. There will be a telephone follow up at one month and parents will be invited for extended telephone interviews within a further month. Comprehensive screening logs will address the primary outcome of recruitment and timeliness until enrolment. Remaining timeliness and adherence outcomes will be recorded in individual participant records and described using CONSORT diagrams. Acceptability will be measured using a mixed method qualitative approach based on the theory of acceptability framework. Discussion: This pragmatically designed trial will address key feasibility points needed to inform a future, definitive multi-centre RCT prospectively testing the role of respiratory virus testing to randomise children with PW to receive oral corticosteroids or not. Trial registration: NCT06580600 ( clinicaltrials.gov )
Open AccessA single centre randomised, feasibility study using point-of-care (POC) testing for respiratory viruses to direct oral corticosteroids use in preschool-aged children with acute wheeze. A Protocol
Background: Wheezing in the pre-school aged group (under 5 years) is a common presentation and significant healthcare burden. It is a heterogenous presentation representing a spectrum of phenotypes and although the causes may be multifactorial, viral infection is the most common trigger, with rhinovirus and Respiratory Syncytial Virus (RSV) being the most commonly detected. Rigorous evidence-based guidance for the acute management of preschool wheeze (PW) with respect to which children likely to benefit from oral corticosteroid therapy (OCS), is lacking. RCTs of OCS use in PW have not adequately assessed the impact of respiratory virus testing in the management of PW. To address the hypothesis that OCS response may be determined by the specific virus, the feasibility of performing POC respiratory virus tests prior to randomisation in an acute paediatric ED setting needs to be ascertained. Methods: The PRECISE Study will be a single centre, randomised, open-label, feasibility trial. Children aged 24-59 months with acute wheeze will be eligible if the clinician is uncertain if there is a role for oral corticosteroid therapy or not. At enrolment, participants will undergo a nasal swab for rapid respiratory virus testing. Children will be randomised in a 1:1 ratio to receive oral dexamethasone or not, based on their RSV result. Participants will continue to be managed by the clinician according to local guidance. They will be invited for clinical review at 72 hours where a repeat nasal swab may be performed. There will be a telephone follow up at one month and parents will be invited for extended telephone interviews within a further month. Comprehensive screening logs will address the primary outcome of recruitment and timeliness until enrolment. Remaining timeliness and adherence outcomes will be recorded in individual participant records and described using CONSORT diagrams. Acceptability will be measured using a mixed method qualitative approach based on the theory of acceptability framework. Discussion: This pragmatically designed trial will address key feasibility points needed to inform a future, definitive multi-centre RCT prospectively testing the role of respiratory virus testing to randomise children with PW to receive oral corticosteroids or not. Trial registration: NCT06580600 ( clinicaltrials.gov )